{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:48:19Z","timestamp":1791863299854,"version":"4.3.4"},"reference-count":27,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Efficient collection of hematopoietic progenitor cells (HPCs) is essential for autologous stem cell transplantation (ASCT) in multiple myeloma (MM). Although plerixafor is routinely used in poor mobilizers, its role in patients with intermediate mobilization capacity remains unclear. In this randomized, double\u2010blind, placebo\u2010controlled phase IV trial, MM patients with peripheral blood (PB) CD34\n                    <jats:sup>+<\/jats:sup>\n                    counts of 15\u201340\u2009cells\/\u03bcL after steady\u2010state G\u2010CSF mobilization were randomized to receive plerixafor or placebo. The primary endpoint was successful collection of \u2265\u20096.0\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    CD34\n                    <jats:sup>+<\/jats:sup>\n                    cells\/kg, sufficient for two ASCTs, during a single apheresis session. Secondary endpoints included CD34\n                    <jats:sup>+<\/jats:sup>\n                    kinetics, graft composition, colony\u2010forming capacity, engraftment, immune reconstitution, and safety. Twenty\u2010one patients were enrolled before premature study termination due to changes in first\u2010line MM therapy and the COVID\u201019 pandemic. Plerixafor significantly increased PB CD34\n                    <jats:sup>+<\/jats:sup>\n                    cell counts compared with placebo (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). All patients receiving plerixafor achieved the primary endpoint, whereas none in the placebo group achieved it (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Mean CD34\n                    <jats:sup>+<\/jats:sup>\n                    yield was significantly higher with plerixafor (10.4\u2009\u00b1\u20091.9\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    \/kg vs. 2.9\u2009\u00b1\u20091.3\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    \/kg;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Plerixafor\u2010mobilized grafts contained significantly higher numbers of primitive hematopoietic progenitor subsets and demonstrated increased CFU\u2010GM formation, indicating enhanced clonogenic potential. Despite marked differences in graft quantity and quality, engraftment kinetics, graft sustainability, and immune reconstitution were comparable between groups. In MM patients with intermediate mobilization capacity, the addition of plerixafor markedly improved stem cell mobilization efficiency and enriched grafts with functionally robust progenitor cells. These findings suggest that selected patients beyond conventional poor mobilizers may benefit from plerixafor\u2010assisted mobilization.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    EudraCT nr.: 2016\u2010004122\u201041\n                  <\/jats:p>","DOI":"10.1002\/jca.70188","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:36:29Z","timestamp":1791862589000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plerixafor and G\u2010\n                    <scp>CSF<\/scp>\n                    Versus Placebo and G\u2010\n                    <scp>CSF<\/scp>\n                    in Moderately Mobilizing Patients With Multiple Myeloma to Optimize Hematopoietic Stem Cell Collection Results (\n                    <scp>OPTIMIZE<\/scp>\n                    )"],"prefix":"10.1002","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3599-8099","authenticated-orcid":false,"given":"Worel","family":"Nina","sequence":"first","affiliation":[{"name":"Department of Transfusion Medicine and Cell Therapy Medical University Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-9715","authenticated-orcid":false,"given":"Schreder","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I Center for Oncology and Hematology, Clinic Ottakring  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanzmann","family":"Andreas","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Cell Therapy Medical University Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2002-8284","authenticated-orcid":false,"given":"Kurz","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Cell Therapy Medical University Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huber\u2010Kra\u00dfnitzer","family":"Bianca","sequence":"additional","affiliation":[{"name":"Division of Hematology Medical University of Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neumeister","family":"Peter","sequence":"additional","affiliation":[{"name":"Division of Hematology Medical University of Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosskopf","family":"Konrad","sequence":"additional","affiliation":[{"name":"Department of Blood Group Serology and Transfusion Medicine Medical University of Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareban","family":"Nazanin","sequence":"additional","affiliation":[{"name":"Department of Blood Group Serology and Transfusion Medicine Medical University of Graz  Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Manuela","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Cell Therapy Medical University Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kolovratova","family":"Vera","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Cell Therapy Medical University Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oesterreicher","family":"Sophia","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Cell Therapy Medical University Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koerbler","family":"Beatrix","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Cell Therapy Medical University Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitzweger","family":"Elvira","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II Clinic Donaustadt  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruckser","family":"Reinhard","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II Clinic Donaustadt  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabitsch","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, BMT\u2010Unit Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-0211","authenticated-orcid":false,"given":"Agis","family":"Hermine","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology &amp; Hemostaseology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krauth","family":"Maria","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology &amp; Hemostaseology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greinix Hildegard","family":"T.","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, BMT\u2010Unit Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple Myeloma: 2024 Update on Diagnosis, Risk\u2010Stratification, and Management","volume":"99","author":"Rajkumar S. V.","year":"2024","journal-title":"American Journal of Hematology"},{"key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo A.","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41409-024-02490-1","article-title":"Single Versus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma","volume":"60","author":"Grieb N.","year":"2025","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clml.2021.08.008","article-title":"Second Autologous Stem Cell Transplant as Salvage in Multiple Myeloma \u2010 The Oregon Health and Science University Experience","volume":"22","author":"Galligan D.","year":"2022","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa2505133","article-title":"Measurable Residual Disease\u2013Guided Therapy in Newly Diagnosed Myeloma","volume":"393","author":"Perrot A.","year":"2025","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbmt.2011.10.003","article-title":"Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated With Fludarabine or Lenalidomide","volume":"18","author":"Malard F.","year":"2012","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous Haematopoietic Stem Cell Mobilisation in Multiple Myeloma and Lymphoma Patients: A Position Statement From the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty M.","year":"2014","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab Before and After Autologous Stem\u2010Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open\u2010Label, Phase 3 Study","volume":"394","author":"Moreau P.","year":"2019","journal-title":"Lancet"},{"key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld P.","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig C.","year":"2015","journal-title":"Lancet"},{"key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1080\/10428194.2023.2253479","article-title":"Impact of Daratumumab on Stem Cell Mobilization and Collection, Engraftment and Early Post\u2010Transplant Complications Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation","volume":"64","author":"Eleutherakis Papaiakovou E.","year":"2023","journal-title":"Leukemia & Lymphoma"},{"key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G\u2010CSF Versus Placebo and G\u2010CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients With Multiple Myeloma","volume":"113","author":"DiPersio J. F.","year":"2009","journal-title":"Blood"},{"key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations","volume":"20","author":"Giralt S.","year":"2014","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"e_1_2_13_15_1","unstructured":"European Medicines Agency (EMA) \u201cPlerixafor (Mozobil): Summary of Product Characteristics \u201d(2016) https:\/\/ec.europa.eu\/health\/documents\/community\u2010register\/2016\/20160302134414\/anx_134414_en.pdf."},{"key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1537-2995.2011.03206.x","article-title":"Efficacy and Cost\u2010Benefit Analysis of Risk\u2010Adaptive Use of Plerixafor for Autologous Hematopoietic Progenitor Cell Mobilization","volume":"52","author":"Vishnu P.","year":"2012","journal-title":"Transfusion"},{"key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1537-2995.2011.03136.x","article-title":"Effectiveness and Cost Analysis of \u2018Just\u2010In\u2010Time\u2019 Salvage Plerixafor Administration in Autologous Transplant Patients With Poor Stem Cell Mobilization Kinetics","volume":"51","author":"Li J.","year":"2011","journal-title":"Transfusion"},{"key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/trf.14182","article-title":"Influence of Plerixafor on the Mobilization of CD34+ Cell Subpopulations and Lymphocyte Subtypes","volume":"57","author":"Worel N.","year":"2017","journal-title":"Transfusion"},{"key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/jca.21496","article-title":"Plerixafor as Preemptive Strategy Results in High Success Rates in Autologous Stem Cell Mobilization Failure","volume":"32","author":"Worel N.","year":"2017","journal-title":"Journal of Clinical Apheresis"},{"key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/bmt.2016.88","article-title":"Multi\u2010Color Immune\u2010Phenotyping of CD34 Subsets Reveals Unexpected Differences Between Various Stem Cell Sources","volume":"51","author":"Dmytrus J.","year":"2016","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_13_21_1","first-page":"267","volume-title":"Colony Forming Cell Assays for Human Hematopoietic Progenitor Cells","author":"Wognum B.","year":"2013"},{"key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","article-title":"AMD3100 Plus G\u2010CSF Can Successfully Mobilize CD34+ Cells From Non\u2010Hodgkin's Lymphoma, Hodgkin's Disease and Multiple Myeloma Patients Previously Failing Mobilization With Chemotherapy and\/or Cytokine Treatment: Compassionate Use Data","volume":"41","author":"Calandra G.","year":"2008","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/bmt.2010.249","article-title":"Plerixafor With and Without Chemotherapy in Poor Mobilizers: Results From the German Compassionate Use Program","volume":"46","author":"H\u00fcbel K.","year":"2011","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bmt.2011.82","article-title":"Proposed Definition of \u2018Poor Mobilizer\u2019 in Lymphoma and Multiple Myeloma: An Analytic Hierarchy Process by Ad Hoc Working Group Gruppo ItalianoTrapianto di Midollo Osseo","volume":"47","author":"Olivieri A.","year":"2012","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41409-024-02233-2","article-title":"Autologous Stem Cell Boost Improves Persistent Immune Effector Cell Associated Hematotoxicity Following BCMA Directed Chimeric Antigen Receptor T (CAR T) Cell Therapy in Multiple Myeloma","volume":"59","author":"Mohan M.","year":"2024","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_13_26_1","first-page":"2460","article-title":"How I Treat Cytopenias After CAR T\u2010Cell Therapy","volume":"141","author":"Jain T.","year":"2023","journal-title":"Blood"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010026\u201001469\u2010z"},{"key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune Effector Cell\u2013Associated Hematotoxicity: EHA\/EBMT Consensus Grading and Best Practice Recommendations","volume":"142","author":"Rejeski K.","year":"2023","journal-title":"Blood"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.70188","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jca.70188","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.70188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:36:35Z","timestamp":1791862595000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.70188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/jca.70188"],"URL":"https:\/\/doi.org\/10.1002\/jca.70188","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70188"}}